T. Rowe Price Associates’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

T. Rowe Price Associates’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-753,595	Closed	-$1.4M	–	3006
2022 Q3	$1.4M	Sell	753,595 -532,729	-41%	-$1.59M	﹤0.01%	1599
2022 Q2	$3.95M	Sell	1,286,324 -530,235	-29%	-$3.24M	﹤0.01%	1452
2022 Q1	$13.1M	Sell	1,816,559 -1,395,916	-43%	-$13.7M	﹤0.01%	1328
2021 Q4	$52.1M	Buy	3,212,475 +1,545,784	+93%	+$18M	﹤0.01%	989
2021 Q3	$16.6M	Sell	1,666,691 -1,942	-0.1%	-$19.3K	﹤0.01%	1343
2021 Q2	$16.7M	Sell	1,668,633 -42,222	-2%	-$424K	﹤0.01%	1340
2021 Q1	$17M	Buy	+1,710,855	New	+$17.7M	﹤0.01%	1311

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

T. Rowe Price Associates's PRDS Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q4 2022, closing a stake of 753,595 shares — an estimated $1.4M sold.

T. Rowe Price Associates first reported a position in PRDS in Q1 2021 and held it in 7 quarters. The position peaked at $52.1M in Q4 2021. 65 funds tracked by Wall St. Rank hold PRDS as of Q4 2022.

T. Rowe Price Associates reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
T. Rowe Price Associates sold 753,595 Pardes Biosciences, Inc. Common Stock shares in Q4 2022, an estimated $1.4M.
T. Rowe Price Associates first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
T. Rowe Price Associates's Pardes Biosciences, Inc. Common Stock position peaked at $52.1M in Q4 2021.
65 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.